Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025892 | 0.82 | HSD17B10 (0.56) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL8820653 | 0.82 | CYP3A4 (0.61) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL23706746 | 0.78 | CYP3A4 (0.60) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL11948618 | 0.78 | AKR1C3 (0.53) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL10316093 | 0.78 | CYP3A4 (0.68) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL20503756 | 0.78 | AKR1C4 (0.44) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL11881446 | 0.77 | HPGD (0.59) | CA1ALDH1A1CA12CA9TSHR | |
| SCHEMBL907550 | 0.76 | CA12 (0.60) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL29421908 | 0.76 | CA12 (0.60) | CA1CA2ALDH1A1CA12CA7 | |
| SCHEMBL2127547 | 0.74 | CYP3A4 (0.59) | CA1CA2ALDH1A1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0623339-B1 | Use of 4-,4- and 5-, or 4- and 6-substituted derivatives of resorcin in cosmetic or dermopharmaceutical compositions for depigmentation | OREAL (FR) | 1997-07-23 | — | — | EP | claimed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1340744-A2 | Hiv protease inhibitors | Agouron Pharmaceuticals, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5952343-A | VIRICIDES; SPECIFICITY; NONTOXIC | AGOURON PHARMACEUTICALS, INC. | 1999-09-14 | — | — | US | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827858-A | ADMINISTERED TO TREAT AIDS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| EP-0741719-A4 | INTERMEDIATE AND PROCESS FOR MAKING | LILLY CO ELI (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0741719-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | CA1 4146/4885CA2 3778/4885ALDH1A1 3232/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | CA1 2796/4885CA2 3472/4885ALDH1A1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.